

RESEARCH ARTICLE

OPEN ACCESS

Genetic Variant of SARS-CoV-2 Isolates in Indonesia: Spike Glycoprotein Gene

Arif Nur Muhammad Ansori^{1,2,3} , Viol Dhea Kharisma^{2,3,4}, Sahal Sabilil Muttaqin⁵, Yulanda Antonius^{2,6} and Arli Aditya Parikesit^{7*} 

¹Doctoral Program in Veterinary Science, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, Indonesia. ²Division of Molecular Biology and Genetics, Generasi Biologi Indonesia (GENBINESIA) Foundation, Gresik, Indonesia. ³Department of Biotechnology, Faculty of Mathematics and Natural Sciences, Universitas Negeri Malang, Malang, Indonesia. ⁴Master Program in Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya, Malang, Indonesia. ⁵Faculty of Biology, Universitas Gadjah Mada, Yogyakarta, Indonesia. ⁶Department of Biology, Faculty of Biotechnology, University of Surabaya, Surabaya, Indonesia. ⁷Department of Bioinformatics, School of Life Sciences, Indonesia International Institute for Life Sciences, Jakarta, Indonesia.

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel coronavirus and the primary causative agent of coronavirus disease 2019 (COVID-19), first occurred in China and rapidly spread worldwide. The government of the Republic of Indonesia confirmed its first two cases of COVID-19 in March 2020. COVID-19 is a serious illness with no efficacious antiviral medication or approved vaccine currently available. Therefore, there is a need to investigate the genome of SARS-CoV-2. In this study, we characterized SARS-CoV-2 spike glycoprotein genes from Indonesia to investigate their genetic composition and variability. Overall, ten SARS-CoV-2 spike glycoprotein gene sequences retrieved from GenBank (National Center for Biotechnology Information, USA) and the GISAID EpiCoV database (Germany) were compared. We analyzed nucleotide variants and amino acid changes using Molecular Evolutionary Genetics Analysis (MEGA) X and analyzed gene similarity using the LALIGN web server. Interestingly, we revealed several specific mutation sites, however, there were no significant changes in the genetic composition of SARS-CoV-2 spike glycoprotein genes, when compared to the Wuhan-Hu-1 isolate from China. However, this is a preliminary study and we recommend that molecular epidemiology and surveillance programs against COVID-19 in Indonesia be improved.

Keywords: Coronavirus, COVID-19, Genetic composition, Mutation, SARS-CoV-2

*Correspondence: arli.parikesit@i3l.ac.id

(Received: May 10, 2020; accepted: May 26, 2020)

Citation: Ansori ANM, Kharishma VD, Muttaqin SS, Antonius Y, Parikesit AA. Genetic Variant of SARS-CoV-2 Isolates in Indonesia: Spike Glycoprotein Gene. *J Pure Appl Microbiol.* 2020;14(suppl 1):971-978. doi: 10.22207/JPAM.14.SPL1.35

© The Author(s) 2020. **Open Access.** This article is distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

INTRODUCTION

The Chinese government first reported a novel pneumonia-causing disease in Wuhan in December 2019¹. The causative agent was identified and named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV)². This new virus has rapidly spread across China and to many other countries across the world, including Indonesia³⁻⁴. The World Health Organization has named the illness caused by SARS-CoV-2 as coronavirus disease 2019 (COVID-19)⁵.

According to an online interactive dashboard hosted by the Center for Systems Science and Engineering at Johns Hopkins University (Baltimore, USA), which tracks reported cases of COVID-19 in real-time⁶, more than 4 million people have been infected by SARS-CoV-2 worldwide, with more than 14 000 cases in Indonesia alone. Currently, there are three coronaviruses that cause illness in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2⁷.

Taxonomically, coronaviruses belong to the *Coronaviridae* family in the order *Nidovirales*, with examples in four distinct genera: *Alphacoronavirus*, *Betacoronavirus*, *Deltacoronavirus*, and *Gammacoronavirus*⁸. The structural proteins are encoded by four genes, specifically the envelope (E), nucleocapsid (N), membrane (M), and spike glycoprotein (S)^{7,9-10}. Previous studies have shown that the spike glycoprotein plays a crucial role in binding to receptors on the host cell. Therefore, this protein is a key target for a number of antiviral therapies and a promising antigen for generating vaccines formulated against SARS-CoV, MERS-CoV, and SARS-CoV-2.

Molecular epidemiology research is a crucial tool in the surveillance of newly emerging and reemerging viruses¹¹⁻¹². Indonesia was the eighth country in Southeast Asia after Brunei, Cambodia, Malaysia, Myanmar, Singapore, Thailand, and Vietnam to report the whole-genome sequences of SARS-CoV-2 in the region. Both Callaway (2020) and Shang *et al.* (2020) have shown that vaccines are being developed against SARS-CoV-2 by various research groups

worldwide¹³⁻¹⁴. Similarly, Al-Tawfiq (2020) has discussed other potential therapeutic options for COVID-19¹⁵ and both remdesivir and chloroquine are capable of effectively inhibiting SARS-CoV-2 in *in vitro* assays¹⁶. Despite these promising treatment options, COVID-19 remains a serious disease with no proven effective antiviral medication or approved vaccine available. Therefore, there is an urgent need to investigate the genome of SARS-CoV-2. In this study, we characterized SARS-CoV-2 spike glycoprotein genes from Indonesia in order to investigate their genetic composition and the similarity between different gene isolates.

MATERIALS AND METHODS

SARS-CoV-2 Isolates

SARS-CoV-2 spike glycoprotein gene (3822 bp) sequences were obtained from GenBank (National Center for Biotechnology Information, USA) and the Global Initiative on Sharing All Influenza Data (GISAID) EpiCoV database (Germany) (Table 1).

Genetic Composition Analysis

We analyzed the genetic composition of SARS-CoV-2 spike glycoproteins (both nucleotide variants and amino acid changes) using Molecular Evolutionary Genetics Analysis (MEGA) X^{12,17}. We used the Wuhan-Hu-1 isolate as a reference gene, according to Sekizuka *et al.* (2020)¹⁸.

Similarity Analysis

We analyzed the similarity of SARS-CoV-2 spike glycoprotein genes using the LALIGN web server (The SIB Swiss Institute of Bioinformatics, Switzerland) with an E-value threshold of 10.0. The LALIGN program is based on an algorithm first described by Huang and Miller¹⁹.

RESULTS AND DISCUSSION

Coronaviruses infect both animals and humans and lead to various illnesses, including neurological, enteric, and respiratory diseases. There are four distinct genera of coronaviruses: *Alphacoronavirus*, *Betacoronavirus*, *Gammacoronavirus*, and *Deltacoronavirus*⁸. SARS-CoV, MERS-CoV, and SARS-CoV-2 are three highly pathogenic coronaviruses, capable of infecting humans, that emerged in 2002, 2012, and 2019, respectively³⁻⁴. In this study, the genetic compositions and sequence similarities of nine Indonesian SARS-CoV-2 spike glycoprotein genes

Table 1. SARS-CoV-2 isolates obtained from the GenBank and GISAID EpiCoV databases

| No | Accession ID | Virus Name | Origin | Submitting Institution | Host | Specimen Source | Coverage |
|----|---------------------------|--------------|-------------------------|--|---------------------|---|----------------------------|
| 1 | MN908947.3 (Reference) | Wuhan-Hu-1 | China (Wuhan) | Shanghai Public Health Clinical Center and School of Public Health, Fudan University, Shanghai | <i>Homo sapiens</i> | Unknown | Reference genome 22x |
| 2 | EPI_ISL_435281 | JKT-EIJK0141 | Indonesia (Jakarta) | Eijkman Institute for Molecular Biology, Ministry of Research and Technology/ National Agency for Research and Innovation of the Republic of Indonesia | <i>Homo sapiens</i> | Nasopharyngeal and Oro- pharyngeal swab | 1,480x |
| 3 | EPI_ISL_435282 | JKT-EIJK0317 | Indonesia (Jakarta) | Eijkman Institute for Molecular Biology, Ministry of Research and Technology/ National Agency for Research and Innovation of the Republic of Indonesia | <i>Homo sapiens</i> | Nasopharyngeal and Oro- pharyngeal swab | 8,082x |
| 4 | EPI_ISL_435283 | JKT-EIJK2444 | Indonesia (Jakarta) | Eijkman Institute for Molecular Biology, Ministry of Research and Technology/ National Agency for Research and Innovation of the Republic of Indonesia | <i>Homo sapiens</i> | Nasopharyngeal swab | 764x |
| 5 | EPI_ISL_437187 | EJ-ITD853Sp | Indonesia (Surabaya) | Institute of Tropical Disease, Universitas Airlangga | <i>Homo sapiens</i> | Sputum | 96x |
| 6 | EPI_ISL_437188 | EJ-ITD3590NT | Indonesia (Surabaya) | Institute of Tropical Disease, Universitas Airlangga | <i>Homo sapiens</i> | Nasopharyngeal and Oro- pharyngeal swab | 2,256x |
| 7 | EPI_ISL_437189 | JKT-EIJK01 | Indonesia (Jakarta) | Eijkman Institute for Molecular Biology, Ministry of Research and Technology/ National Agency for Research and Innovation of the Republic of Indonesia | <i>Homo sapiens</i> | Nasopharyngeal and Oro- pharyngeal swab | 5,297x |
| 8 | EPI_ISL_437190 | JKT-EIJK02 | Indonesia (Jakarta) | Eijkman Institute for Molecular Biology, Ministry of Research and Technology/ National Agency for Research and Innovation of the Republic of Indonesia | <i>Homo sapiens</i> | Nasopharyngeal swab | 2,112x |
| 9 | EPI_ISL_437191 | JKT-EIJK03 | Indonesia (Jakarta) | Eijkman Institute for Molecular Biology, Ministry of Research and Technology/ National Agency for Research and Innovation of the Republic of Indonesia | <i>Homo sapiens</i> | Nasopharyngeal and Oro- pharyngeal swab | 5,759x |
| 10 | EPI_ISL_437192 | JKT-EIJK04 | Indonesia (Jakarta) | Eijkman Institute for Molecular Biology, Ministry of Research and Technology/ National Agency for Research and Innovation of the Republic of Indonesia | <i>Homo sapiens</i> | Nasopharyngeal and Oro- pharyngeal swab | |

Table 2. Nucleotide mutation sites in the SARS-CoV-2 spike glycoprotein

| No. | Virus Name | Nucleotide Position | | | | | | | |
|-----|------------------------|---------------------|-----|-----|------|------|------|------|------|
| | | 224 | 347 | 414 | 1715 | 1841 | 1864 | 2031 | 2464 |
| 1 | Wuhan-Hu-1 (Reference) | C | C | T | C | A | G | G | C |
| 2 | JKT-EIJK0141 | C | C | T | C | A | G | G | C |
| 3 | JKT-EIJK0317 | C | C | T | C | A | G | G | C |
| 4 | JKT-EIJK2444 | T | C | T | C | A | G | G | C |
| 5 | EJ-ITD853Sp | C | C | T | C | A | G | G | C |
| 6 | EJ-ITD3590NT | C | G | T | C | G | G | T | C |
| 7 | JKT-EIJK01 | C | C | C | C | A | T | G | C |
| 8 | JKT-EIJK02 | C | C | T | C | A | G | G | C |
| 9 | JKT-EIJK03 | C | C | T | C | A | G | G | C |
| 10 | JKT-EIJK04 | C | C | T | T | A | G | G | T |

Table 3. Amino acid mutation sites in the SARS-CoV-2 spike glycoprotein

| No | Virus Name | Amino Acid Position | | | | | | |
|----|------------------------|---------------------|-----|-----|-----|-----|-----|-----|
| | | 76 | 116 | 572 | 614 | 622 | 677 | 822 |
| 1 | Wuhan-Hu-1 (Reference) | T | S | T | D | V | Q | L |
| 2 | JKT-EIJK0141 | T | S | T | D | V | Q | L |
| 3 | JKT-EIJK0317 | T | S | T | D | V | Q | L |
| 4 | JKT-EIJK2444 | I | S | T | D | V | Q | L |
| 5 | EJ-ITD853Sp | T | S | T | D | V | Q | L |
| 6 | EJ-ITD3590NT | T | C | T | G | V | H | L |
| 7 | JKT-EIJK01 | T | S | T | D | F | Q | L |
| 8 | JKT-EIJK02 | T | S | T | D | V | Q | L |
| 9 | JKT-EIJK03 | T | S | T | D | V | Q | L |
| 10 | JKT-EIJK04 | T | S | I | D | V | Q | F |

were determined using sequences obtained from GenBank and the GISAID EpiCoV database (Table 2-4). Many researchers worldwide have previously reported mutations in the SARS-CoV-2 genome^{10,20-21}, however, there has not previously been a study of the SARS-CoV-2 genome from Indonesian isolates.

The coronavirus spike glycoprotein mediates membrane fusion and viral entry into host cells and is therefore the primary target for many neutralizing antibodies (Fig. 1). The spike glycoprotein has two domains, S1 and S2, where S1 is responsible for binding the virion to ACE2 on the host cell membrane²¹. Several antiviral drugs and vaccines have been developed which target the spike glycoprotein. Du *et al.* (2009)²² demonstrated the effectiveness of several of these antiviral therapies, including small interfering

RNAs, protease inhibitors, ACE2 blockers, fusion blockers, spike glycoprotein inhibitors, neutralizing antibodies, and spike glycoprotein cleavage inhibitors in *in vitro* studies. In addition, a number of techniques have been used to generate vaccines using all or part of the spike glycoprotein as an antigen. These include the use of recombinant receptor binding domain protein, viral vectors, full-length S protein, recombinant spike glycoprotein, and spike protein DNA-expressing vectors. Thus, it is very important to investigate the genetic composition and sequence similarity of this protein.

Interestingly, despite reporting several mutation sites in this study, we demonstrate that there is no significant change in the genetic composition of SARS-CoV-2 spike glycoprotein genes. Nucleotide variants in SARS-CoV-2 spike

Table 4. Sequence similarity of SARS-CoV-2 spike glycoprotein genes, determined using the LALIGN web server

| Virus Name | Similarity | | | | | | | | | |
|--------------|---------------------------|--------------|--------------|--------------|-------------|--------------|------------|------------|------------|--|
| | Wuhan-Hu-1 (Reference) | JKT-EIJK0141 | JKT-EIJK0317 | JKT-EIJK2444 | EJ-ITD853Sp | EJ-ITD3590NT | JKT-EIJK01 | JKT-EIJK02 | JKT-EIJK03 | |
| JKT-EIJK0141 | 100% | | | | | | | | | |
| JKT-EIJK0317 | 100% | 100% | | | | | | | | |
| JKT-EIJK2444 | 100% | 100% | 100% | | | | | | | |
| EJ-ITD853Sp | 100% | 100% | 100% | 100% | | | | | | |
| EJ-ITD3590NT | 99.9% | 99.9% | 99.9% | 99.9% | 99.9% | | | | | |
| JKT-EIJK01 | 99.9% | 99.9% | 99.9% | 99.9% | 99.9% | 99.9% | 99.9% | | | |
| JKT-EIJK02 | 100% | 100% | 100% | 100% | 100% | 99.9% | 99.9% | 100% | | |
| JKT-EIJK03 | 100% | 100% | 100% | 100% | 100% | 99.9% | 99.9% | 99.9% | | |
| JKT-EIJK04 | 99.9% | 99.9% | 99.9% | 99.9% | 99.9% | 99.9% | 99.9% | 99.9% | 99.9% | |

glycoprotein genes described in this study include JKT-EIJK2444 (224C>T), EJ-ITD3590NT (347C>G; 1841A>G; 2031G>T), JKT-EIJK01 (414T>C; 1864G>T), and JKT-EIJK04 (1715C>T; 2464C>T) (Table 2). In addition, we also analyzed amino acid changes in the SARS-CoV-2 spike glycoprotein including JKT-EIJK2444 (T76I), EJ-ITD3590NT (S116C; D614G; Q677H), JKT-EIJK01 (V622F), and JKT-EIJK04 (T572I; L822F) (Table 3). Finally, the interval score of similarity between each of the SARS-CoV-2 spike glycoproteins was between 99.9% and 100% (Table 4).

Previous studies investigating gene variability in SARS-CoV-2 samples include the work of Sekizuka *et al.* (2020), who performed whole-genome sequencing of SARS-CoV-2, directly from PCR-positive clinical specimens¹⁸. This was conducted in order to generate a haplotype network analysis of the Diamond Princess cruise ship outbreak, using the Wuhan-Hu-1 sequence as a reference. Additionally, Castillo *et al.* (2020) reported a phylogenetic analysis of the first four SARS-CoV-2 cases in Chile, analyzing nucleotide variants, amino acid changes, and sequence similarity²³. While our study complements these previous works, several shortcomings remain, including the relatively small number of isolates studied, the methodology used for whole-genome sequencing, and the quality coverage of SARS-CoV-2 genomes isolated from Indonesia.

As new information on SARS-CoV-2 is published daily, new concepts and frameworks must constantly be adopted. Currently, the GISAID EpiCoV database and Tang *et al.* (2020) have established three subtypes of SARS-CoV-2 based on nucleotide variants that produce amino acid changes: S, G, and V²⁴. The mutation rate of viruses is considerably higher than most other biological entities, including prokaryotes and eukaryotes. This is especially true of RNA-based viruses such as SARS-CoV-2, Ebola and dengue, due to hydroxyl groups in RNA that act as catalytic sites for mutation. This advanced mutation rate, leads to enhanced virulence and a higher capacity for adaptive evolution²⁵⁻²⁶. While Tang *et al.* (2020) have suggested that SARS-CoV-2 exhibits the characteristic high mutation rate of an RNA virus²⁴, in fact, the mutation rate of SARS-CoV-2 and other coronaviruses might be slightly lower than other RNA viruses because of its genome-encoded




Fig. 1. Schematic diagram of SARS-COV and SARS-CoV-2 binding with high affinity to ACE2, an essential step in viral entry into host cells.

exonuclease. Regardless, its high mutation rate increases the potential of this zoonotic viral pathogen to adapt to efficient transmission from human to human and potentially allows it to become more virulent.

The genomic characteristics of SARS-CoV-2 are significantly different than either SARS-CoV or MERS-CoV²⁷. A previous study reported that the homology of SARS-CoV-2 with the bat coronavirus isolate, RaTG13, was 96%²⁸. Interestingly, another study reported that the homology of SARS-CoV-2 with a pangolin coronavirus was 99%¹. From these results, it could be suggested that pangolins act as an intermediate host between bats and humans.

This study of genomic variants of SARS-CoV-2 isolated from Indonesia is crucial for future investigations into the pathogenesis, prevention, and treatment of SARS-CoV-2. Development of this genomic data is vital work that will facilitate vaccine design, epidemiological investigations, viral detection, functional analysis, and evaluation of treatment options²⁷.

Outbreaks of SARS-CoV-2 have led to a state of medical and economic emergency worldwide. Therefore, understanding the characteristics of the SARS-CoV-2 genome and developing systems to monitor SARS-CoV-2 during the pandemic are critical steps for controlling this disease. The identification of genotypes connected

to specific geographic and temporal infectious clusters suggests that genomic data can be used to track and monitor the transmission of SARS-CoV-2. Therefore, the rapid discovery of genetic variants of SARS-CoV-2 is necessary for a streamlined response to the COVID-19 outbreak. Similarly, identifying specific SARS-CoV-2 variants and connecting them using a molecular epidemiology approach would allow researchers to determine the origin of a specific variant and monitor its transmission. This could be an important tool in controlling the outbreak²¹.

CONCLUSION

In summary, there was no significant difference between the SARS-CoV-2 spike glycoprotein gene sequences found in Indonesia and the Wuhan-Hu-1 isolate from China. However, this was only a preliminary study and we recommend expanding molecular epidemiology and surveillance programs to monitor COVID-19 in Indonesia.

ACKNOWLEDGMENTS

This study was supported by the Directorate General of Higher Education, Ministry of Education and Culture of the Republic of Indonesia; the Institute of Research and Community Empowerment (LPPM) of the Indonesia International Institute for Life Sciences

(I3L); and Generasi Biologi Indonesia (GENBINESIA) Foundation, Indonesia. We thank Editage for editing the manuscript.

CONFLICT OF INTEREST

The authors declares that there is no conflict of interest.

AUTHORS' CONTRIBUTION

All listed authors made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING

PMDSU Scholarship Batch III from the Directorate General of Higher Education, Ministry of Education and Culture of the Republic of Indonesia.

ETHICS STATEMENT

This article does not contain any experiments using human participants or animals performed by any of the authors.

AVAILABILITY OF DATA

Not applicable.

REFERENCES

- Lam TT, Shum MH, Zhu HC, et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. *Nature*. 2020. <https://doi.org/10.1038/s41586-020-2169-0>
- Gorbalenya AE, Baker SC, Baric RS, et al. The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol*. 2020;5:536-544. <https://doi.org/10.1038/s41564-020-0695-z>
- Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. *Nat Med*. 2020;26:450-452. <https://doi.org/10.1038/s41591-020-0820-9>
- Kharisma VD, Ansori ANM. Construction of epitope-based peptide vaccine against SARS-CoV-2: Immunoinformatics study. *J Pure Appl Microbiol*. 2020;14:6248.
- Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents*. 2020;55:105924. <https://doi.org/10.1016/j.ijantimicag.2020.105924>
- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*. 2020;S1473-3099(20): 30120-30121. [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1)
- Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell*. 2020;181:281-292.e6. <https://doi.org/10.1016/j.cell.2020.02.058>
- Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun*. 2020;11:1620. <https://doi.org/10.1038/s41467-020-15562-9>
- Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res*. 2020;24:91-98. <https://doi.org/10.1016/j.jare.2020.03.005>
- Phan T. Genetic diversity and evolution of SARS-CoV-2. *Infect Genet Evol*. 2020;81:104260. <https://doi.org/10.1016/j.meegid.2020.104260>
- Ansori ANM, Sucipto TH, Deka PT, et al. Differences of universal and multiplex primer for detection of Dengue virus from patients suspected Dengue Hemorrhagic Fever (DHF) in Surabaya. *Indonesian J Trop Infect Dis*. 2015;5:147-151. <https://doi.org/10.20473/ijtid.v5i6.594>
- Ansori ANM, Kharisma VD. Characterization of Newcastle disease virus in Southeast Asia and East Asia: Fusion protein gene. *Eksakta*. 2020;1:20-28. <https://doi.org/10.20885/EKSAKTA.vol1.iss1.art3>
- Callaway E. The race for coronavirus vaccines: A graphical guide. *Nature*. 2020;580:576-577. <https://doi.org/10.1038/d41586-020-01221-y>
- Shang W, Yang Y, Rao Y, Rao X. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. *NPJ Vaccines*. 2020;5:18. <https://doi.org/10.1038/s41541-020-0170-0>
- Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. *Travel Med Infect Dis*. 2020;34:101615. <https://doi.org/10.1016/j.tmaid.2020.101615>
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) *in vitro*. *Cell Res*. 2020;30:269-271. <https://doi.org/10.1038/s41422-020-0282-0>
- Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across computing platforms. *Mol Biol Evol*. 2018;35:1547-1549. <https://doi.org/10.1093/molbev/msy096>
- Sekizuka T, Itokawa K, Kageyama T, et al. Haplotype networks of SARS-CoV-2 infections in the Diamond Princess cruise ship outbreak. *medRxiv*. 2020. <https://doi.org/10.1101/2020.03.23.20041970>
- Joob B, Wiwanitkit V. Genetic variant severe acute respiratory syndrome coronavirus 2 isolates in Thailand. *J Pure Appl Microbiol*. 2020;14:6314. <https://doi.org/10.22207/JPAM.14.SPL1.01>
- Benvenuto D, Angeletti S, Giovanetti M, et al.. Evolutionary analysis of SARS-CoV-2: How mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. *J Infect*. 2020;S0163-4453(20):30186-9. <https://doi.org/10.1016/j.jinf.2020.03.058>
- Yin C. Genotyping coronavirus SARS-CoV-2: methods and implications. *Genomics*. 2020;S0888-

- 7543(20):30318-9. <https://doi.org/10.1016/j.ygeno.2020.04.016>
22. Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. *Nat Rev Microbiol*. 2009; 7: 226e36. <https://doi.org/10.1038/nrmicro2090>
23. Castillo AE, Parra B, Tapia P, Acevedo A, Lagos J, Andrade W, Arata L, Leal G, Barra G, et al. Phylogenetic analysis of the first four SARS-CoV-2 cases in Chile. *J Med Virol*. 2020. [Epub ahead of print] <https://doi.org/10.1002/jmv.25797>
24. Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. *Nat Sci Rev*, 2020; nwaa036.
25. Duffy S. Why are RNA virus mutation rates so damn high? *PLoS Biol*. 2018;16:e3000003. <https://doi.org/10.1371/journal.pbio.3000003>
26. Eyer L, Nencka R, de Clercq E, Seley-Radtke K, Ruzek D. Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. *Antivir Chem Chemother*. 2018;26:2040206618761299. <https://doi.org/10.1177/2040206618761299>
27. Wang C, Liu Z, Chen Z, Huang X, Xu M, He T, Zhang Z. The establishment of reference sequence for SARS-CoV-2 and variation analysis. *J Med Virol*. 2020. <https://doi.org/10.1002/jmv.25762>
28. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579:270-273. <https://doi.org/10.1038/s41586-020-2012-7>

J. Pure Appl. Microbiol.
Volume 14, Spl. Issue May 2020
ISSN: 0973-7510
E-ISSN: 2581-690X

Journal of Pure and Applied Microbiology

An International Peer Reviewed Open Access Research Journal



Special Edition
**Coronaviruses and
COVID-19– Past,
Present, and Future**

JPAM
JOURNAL OF PURE AND APPLIED MICROBIOLOGY


[The Coronavirus Figure was created with "BioRender.com" template and exported under the terms of premium subscription by "Hafiz M. N. Jabbar".]

www.microbiologyjournal.org

Journal of Pure and Applied Microbiology

COUNTRY

India

 Universities and research institutions in India

SUBJECT AREA AND CATEGORY

Biochemistry, Genetics and Molecular Biology
Biotechnology

Immunology and Microbiology
Applied Microbiology and Biotechnology
Microbiology

PUBLISHER

Journal of Pure and Applied
Microbiology

H-INDEX

16

PUBLICATION TYPE

Journals

ISSN

09737510, 2581690X

COVERAGE

2007-2020

INFORMATION

[Homepage](#)

[How to publish in this journal](#)

iahmad.am@amu.ac.in

SCOPE

Journal of Pure and Applied Microbiology is a peer-reviewed, open access, quarterly published international journal of microbiology strives to provide a forum for worldwide scientific researchers, academics, clinicians and microbiologists for publication of high quality reviews, research articles, short communications and clinical studies pertaining to all aspects of microbiology and its allied disciplines. All original articles reporting work on micro-organisms including viruses, bacteria, algae and fungi are welcomed. Articles must present information that is novel, has high impact and interest, and is of high scientific quality that makes significant contribution to the field as a whole.

 Join the conversation about this journal

Quartiles

FIND SIMILAR JOURNALS

options



Show this widget in your own website

Just copy the code below and paste within your html code:

<a href="https://www.scimagojr.com/journalsearch.php?q=11700154322&tip=s..."

SCImago Graphica

Explore, visually communicate and make sense of data with our new free tool.



Cat it

Metrics based on Scopus® data as of April 2021

R **Ravindra v shinde** 2 years ago

Let me know status of my article . Rf id 6153/2020
Manuscript send at the end of Feb 2020.

reply

**Melanie Ortiz** 1 year ago

SCImago Team

Dear Ravindra,
thank you for contacting us.
We are sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus. Unfortunately, we cannot help you with your request, we suggest you contact the journal's editorial staff , so they could inform you more deeply.
Best Regards, SCImago Team

Y **Yermia** 2 years ago

Whether the journal is still indexed in scopus ?

reply

**Melanie Ortiz** 2 years ago

SCImago Team

Dear Yermia, thank you very much for your comment, unfortunately we cannot help you with your request. We suggest you consult the Scopus database directly. Keep in mind that the SJR is a static image (the update is made one time per year) of a database (Scopus) which is changing every day.

R **Rittishai saelim** 2 years ago

This journal is now included in the updated Beall's list of predatory journals. Could anyone verify the validity of this journal please?

reply

D **Dr. M. N. Khan** 2 years ago

Dear Rittishai,
Our journal had-been removed from the Beall's list of potential predatory journals and publishers in their last update dated June 07, 2020. For your reference, you can check it here: <https://beallslist.net/>

For any further information, please feel free to contact us.

Best Regards

Dr. M. N. Khan

Editor

Journal of Pure and Applied Microbiology

www.microbiologyjournal.org

D **Dr. M. N. Khan** 2 years ago

Dear Rittishai,

Thanks for your comment. Kindly note, the current Beall's list (<https://beallslist.net/>) is not updated from December 28, 2019. Also, our journal was not in the Original predatory list created by the librarian Mr. Jeffrey Beall. We have already tried to reach through the contact form couple of times to the anonymous person currently maintaining Beall's list but unfortunately, we haven't received any reply from their side. Our journal is indexed in Scopus (Elsevier), Emerging Sources Citation Index (Web of Science, Clarivate Analytics), DOAJ (Directory of Open Access Journals), CAB Abstracts (CABI), etc.

Moreover, you can read it yourself (<https://beallslist.net/how-to-recognize-predatory-journals/>) clearly mentioned on the current Beall's list website that if a journal is indexed in JCR or/and DOAJ, that is usually a very good indicator that the journal is not predatory.

For any further information, please feel free to contact us at: editor@microbiologyjournal.org

Thanks and Regards

Dr. M. N. Khan
Editor
Journal of Pure and Applied Microbiology
www.microbiologyjournal.org/



Melanie Ortiz 2 years ago

SCImago Team

Dear Rittishai,
thank you very much for your comment, unfortunately we cannot help you with your request. We suggest you contact directly with Scopus support:
https://service.elsevier.com/app/answers/detail/a_id/14883/kw/scimago/supporthub/scopus/
Best Regards, SCImago Team

B Bayar Zeebaree 2 years ago

Dear
could you please inform me which references style I can use for my manuscript

reply



Melanie Ortiz 2 years ago

SCImago Team

Dear Bayar, thank you very much for your comment, we suggest you to look for author's instructions/submission guidelines in the journal's website. Best Regards, SCImago Team

A Abdullahi Balarabe Inuwa 3 years ago

I received an email purportedly from this journal requesting me to contribute an article in the forthcoming edition. The sender's details are as follows: Dr. M.N. Khan:
editor@microbiologyjournal.org, micro_drkhan@yahoo.com. 91-9893809167. Journal of Pure and Applied Microbiology. Please how genuine is this?

Regards,
Abdullahi Balarabe Inuwa

reply

A Azim Aijaz 3 years ago

Dear Abdullahi Balarabe Inuwa,

Greetings from "Journal of Pure and Applied Microbiology"!

It is a genuine journal and is indexed in Scopus.
For further information regarding "Abstracting and Indexing" of Journal and "Instructions to Authors", Kindly visit the following link:
<https://microbiologyjournal.org/indexed-abstracted/>
<https://microbiologyjournal.org/instructions-to-authors/>

If you have any further query feel free to write us on, editor@microbiologyjournal.org

Thanks and Regards

Azim Aijaz



Elena Corera 3 years ago

SCImago Team

Dear Abdullahi Balarabe Inuwa,

we are so sorry, but we cannot help you with your request. We are an institution absolutely different from the journals, so we cannot provide you any information different from what you can find in their websites.

Please, contact journal editorial staff so they could solve your request.

Best regards,
SCImago Team

F **Fatalla** 3 years ago

Dear

I would like to know if the journal continue with scopus coverage in this year 2018

Regards

reply



Elena Corera 3 years ago

SCImago Team

Dear Fatalla,

thank you for your request, all the journals included in SJR are indexed in Scopus. Elsevier / Scopus is our data provider.

Best Regards,
SCImago Team

A **Ameer** 3 years ago

Thanks Elena for this information

reply

J **Jenni** 3 years ago

The web page of the journal not opened and I want to download my paper

reply

J **Jenni** 3 years ago

The web page of the journal do not work please help us we want to download our paper

reply

A

Azim Alijaz 3 years ago

Dear Jenni,

Greetings from Journal of Pure and Applied Microbiology!

Kindly visit the following link to download your paper.

<https://microbiologyjournal.org/archive/>

If you have any further query feel free to write us back.



Elena Corera 3 years ago

SCImago Team

Corrected, thanks!!!

N **Nermin Şimşek Kuş** 3 years ago

Dear editor,

I sent an article ("The synthesis of two novel bicyclic halo ketones and the measurement of their biological activity") in May. But no answer came. Would you give me information about the article.

Prof. dr. Nermin Şimşek Kuş
simner@mersin.edu.tr

reply

**Elena Corera** 3 years ago

SCImago Team

Dear Nermin, we suggest you contact the journal directly. Best Regards, SCImago Team

N nihad 3 years ago

good evening :
I would like to publish my research in your journal

reply

**Elena Corera** 3 years ago

SCImago Team

Dear Nihad, in the link below you will find the information corresponding to the author's instructions of this journal. Best regards, SCImago Team
<http://microbiologyjournal.org/authors-guidelines/>

Leave a comment

Name


Email
(will not be published)**Submit**

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2020. Data Source: Scopus®

EST MODUS IN REBUS
Version (Build) 1.1 (106)



Source details

Journal of Pure and Applied Microbiology

Open Access ⓘ

Scopus coverage years: from 2007 to 2021

Publisher: Journal of Pure and Applied Microbiology

ISSN: 0973-7510 E-ISSN: 2581-690X

Subject area: Immunology and Microbiology: Applied Microbiology and Biotechnology

Biochemistry, Genetics and Molecular Biology: Biotechnology

Immunology and Microbiology: Microbiology

Source type: Journal

CiteScore 2020

0.7

ⓘ

SJR 2020

0.149

ⓘ

SNIP 2020

0.282

ⓘ

View all documents >

Set document alert



Save to source list Source Homepage

CiteScore CiteScore rank & trend Scopus content coverage

Improved CiteScore methodology

CiteScore 2020 counts the citations received in 2017-2020 to articles, reviews, conference papers, book chapters and data papers published in 2017-2020, and divides this by the number of publications published in 2017-2020. [Learn more >](#)

CiteScore 2020

0.7 = $\frac{720 \text{ Citations 2017 - 2020}}{1,081 \text{ Documents 2017 - 2020}}$

Calculated on 05 May, 2021

CiteScoreTracker 2021 ⓘ

1.2 = $\frac{1,256 \text{ Citations to date}}{1,080 \text{ Documents to date}}$

Last updated on 05 January, 2022 • Updated monthly

CiteScore rank 2020 ⓘ

| Category | Rank | Percentile |
|--|----------|------------|
| Immunology and Microbiology | #94/113 | 17th |
| Applied Microbiology and Biotechnology | | |
| Biochemistry, Genetics and Molecular Biology | #234/282 | 17th |
| Biotechnology | | |

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site &](#)

About Scopus

- What is Scopus
- Content coverage
- Scopus blog
- Scopus API
- Privacy matters

Language

- 日本語に切り替える
- 切换到简体中文
- 切换到繁體中文
- Русский язык

Customer Service

- Help
- Contact us

ELSEVIER

[Terms and conditions ↗](#) [Privacy policy ↗](#)

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.
We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.





About JPAM

[About JPAM](#)
[Aims and Scope](#)
[Editorial Board](#)
[Abstracting and Indexing](#)
[Policies](#)
[Revenue Sources](#)
[Contact Us](#)

Journal of Pure and Applied Microbiology (JPAM) is a peer-reviewed, open access international journal of microbiology aims to advance and disseminate research among scientists, academics, clinicians and microbiologists around the world. JPAM publishes high-quality research in all aspects of microbiology in both online and print form on quarterly basis.

Journal Information

Print ISSN: 0973-7510

Online ISSN: 2581-690X

Journal Abbreviation: *J. Pure Appl. Microbiol.*

Frequency: Quarterly (March, June, September & December)

DOI: Prefix 10.22207

Publisher: Dr. M.N. Khan



Print ISSN: 0973-7510

Online ISSN: 2581-690X



All Journal of Pure and Applied Microbiology articles are published under the terms of the

[Creative Commons Attribution 4.0 International](#)

(CC BY 4.0) License.

About JPAM

[Aims and Scope](#)
[Editorial Board](#)
[Abstracting and Indexing](#)
[Open Access Policy](#)
[Copyright and Licensing](#)
[Policy](#)
[Contact Us](#)

Articles

[Current Issue](#)
[Spl. Issue, May 2020](#)
[Articles In Press](#)
[Archive](#)

For Authors

[Article Processing Charges](#)
[Scope of the Journal](#)
[Instructions to Authors](#)
[Review Guidelines](#)
[Policies](#)
[Article Submission Form](#)

For Reviewers

[Scope of the Journal](#)
[Review Guidelines](#)
[Peer Review Policy](#)
[Publication Ethics and Malpractice Statement](#)
[Join our Team of Reviewers](#)
[Our Reviewers](#)

Editorial Board

Editor-in-Chief

Dr. Iqbal Ahmad

Department of Agricultural Microbiology, Aligarh Muslim University, Aligarh, India

Email: iahmad.am@amu.ac.in; ahmadiqbal@yahoo.co.in

<https://orcid.org/0000-0001-8447-4497>



Iqbal Ahmad is currently Professor of the Department of Agricultural Microbiology at Aligarh Muslim University in Aligarh, India. He received his Ph.D. degree from Aligarh Muslim University in Agriculture Microbiology, during his Ph.D. research work he worked at the Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India with pioneer veterinary bacteriologist, Late Dr. JNS Yadava, FNA, FNASc. He first worked as a Research Scientist at The Himalya Drug Co., New Delhi in 1994 and then joined as a Lecturer at the Department of Agricultural Microbiology, Aligarh Muslim University, Aligarh in 1995 and then promoted to Professor in 2010. He was the Section Incharge of Microbiology during 1999-2000 and has also chaired the Department during 2011-2013 and in 2017. He has done pioneering research on plasmid mediated drug resistance and virulence factors in enteric bacteria and strategies to combat drug resistance and virulence of pathogenic microbes through screening and

evaluation of Indian medicinal plant derived herbal products/extracts and phytochemicals especially targeting Quorum sensing, biofilm and virulence of pathogenic microorganisms. His research work on agriculturally important microorganisms on diazotrophs, biofilm forming PGPR and impact of wastewater on soil health has been well documented. His recent interest on interdisciplinary microbiological works and drug-macromolecule interactions are gaining importance in academic world.

Deputy Editor-in-Chief

Dr. Kuldeep Dhama

Division of Pathology, ICAR – Indian Veterinary Research Institute, Bareilly, India

Email: kdhama@rediffmail.com

<https://orcid.org/0000-0001-7469-4752>



Kuldeep Dhama is currently working as Principal Scientist in ICAR-Indian Veterinary Research Institute (IVRI), Izatnagar, India. With 22 years of research and teaching experience in the areas of microbiology, immunology and virology, he has developed several diagnostics, vaccines, immunomodulatory modules and hypothesis to counter infectious diseases of animals, poultry and public health concerns. He also has been awarded NAAS Associateship (National Academy of Agricultural Science, India). To his credit he has handled 20 research projects and guided 17 M.V.Sc. and P.D. scholars.

Associate Editors



Dr. Hafiz M. N. Iqbal

Professor

Tecnológico de Monterrey
School of Engineering and Sciences
Campus Monterrey, C.P. 64849
Monterrey, Nuevo León
Mexico
hafiz.iqbal@tec.mx



Dr. Faisal Masood Khan

Associate Professor

Department of Pathology and Laboratory Medicine,
Faculty of Cumming School of Medicine, Foothills
Campus, Alberta
Canada
fkhan@ucalgary.ca



Dr. Jianxun Ding

Associate Professor

Key Laboratory of Polymer Ecomaterials
Changchun Institute of Applied Chemistry
Chinese Academy of Sciences
Changchun
China
jxding@ciac.ac.cn



Dr. Mohamed Fawzy Ramadan Hassanien

Professor

Department of Biochemistry
Faculty of Agriculture
Zagazig University, Zagazig
Egypt
mframadan@zu.edu.eg



Dr. Ruchi Tiwari 
 Assistant Professor
 Department of Veterinary Microbiology,
 College of Veterinary Sc. & A.H.
 DUVASU, Mathura, U.P.
 India
ruchi.vet@gmail.com




Dr. Javad Sharifi-Rad 
 Assistant Professor
 Phytochemistry Research Center,
 Shahid Beheshti University of Medical Sciences
 Tehran
 Iran
javad.sharifirad@gmail.com




Dr. Yashpal Singh Malik 
 Dean
 College of Animal Biotechnology,
 Guru Angad Dev Veterinary and Animal
 Sciences University (GADVASU), Ludhiana
 India
malikyps@gmail.com




Dr. Ahmet Adiguzel 
 Professor
 Faculty of Science
 Department of Molecular Biology
 and Genetics, Ataturk University
 25240-Erzurum
 Turkey
adiguzel@atauni.edu.tr



Dr. Adriano Gomes da Cruz 
 Professor
 Department of Food,
 Federal Institute of Rio de Janeiro (IFRJ),
 Brazil
adriano.cruz@ifrj.edu.br




Dr. Ian James Martins 
 Principal Research Fellow
 Centre of Excellence for Alzheimer's Disease
 Research and Care,
 Edith Cowan University, Perth
 Australia
i.martins@ecu.edu.au

Assistant Editors



Dr. Muhammad Bilal 
 Associate Professor
 School of Life Science and Food Engineering,
 Huaiyin Institute of Technology, Huai'an,
 China.
bilaluaif@hyit.edu.cn




Dr. Roberto Parra-Saldivar 
 Professor
 Tecnológico de Monterrey,
 School of Engineering and Sciences,
 Monterrey, NL,
 Mexico.
r.parra@tec.mx



Dr. Izabela Michalak 
 Associate Professor
 Department of Advanced Material Technologies,
 Wrocław University of Science and Technology,
 Wrocław,
 Poland.
izabela.michalak@pwr.edu.pl



Dr. Dimitri Poddighe 
 Associate Professor
 School of Medicine (NUSOM),
 Nazarbayev University,
 Nur-Sultan City,
 Kazakhstan.
dimitri.poddighe@nu.edu.kz

Editorial Board Members



Dr. Nikhat Manzoor 
 Professor
 Department of Biosciences
 Jamia Millia Islamia, New Delhi
 India
nmanzoor@jmi.ac.in



Dr. Pramod W. Ramteke 
 Professor and Head
 Department of Biological Sciences
 Sam Higginbottom University of Agriculture
 Technology & Sciences (SHUATS), Allahabad
 India
pramod.ramteke@shiats.edu.in



Dr. Guohua (Karen) Yin 
Microbiologist,
Mycotoxin Prevention and Applied
Microbiology Research Unit,
National Center for Agricultural
Utilization Research, USDA ARS, Peoria, IL
USA
guohua.yin@usda.gov



Dr. Vodnar Dan- Cristian 
Associate Professor
Department of Food Science
University of Agricultural Sciences and Veterinary
Medicine, Cluj-Napoca
Romania
dan.vodnar@usamwcluj.ro



Dr. Maryam Dadar 
Assistant Professor
Agricultural Research, Razi Vaccine and Serum
Research Institute
(RVSRI), Karaj
Iran
dadar.m77@gmail.com



Dr. Abd El-Latif Hesham 
Professor
Department of Genetics
Faculty of Agriculture
Beni-Suef University, Beni-Suef
Egypt
hesham_egypt5@agr.bsu.edu.eg



Dr. Pongsak Rattanachaikunsopon 
Professor
Department of Biological Science
Faculty of Science
Ubon Ratchathani University, Ubon Ratchathani
Thailand
rattanachaikunsopon@yahoo.com




Dr. Vasudeo Zambare 
Professor
School of Science
Sandip University, Nashik Maharashtra,
India
vasuzambare@gmail.com



Dr. Debdulal Banerjee 
Associate Professor
Department of Botany and Forestry
Vidyasagar University, Midnapore, West Bengal
India
db@mail.vidyasagar.ac.in



Dr. Nour Shafik Emam El-Gendy 
Professor
Department of Petroleum and
Environmental Biotechnology
Egyptian Petroleum Research Institute, Cairo
Egypt
nourepri@yahoo.com



Dr. Mona Ibrahim Shaaban 
Associate Professor
Department of Microbiology and Immunology
Faculty of Pharmacy, Mansoura University
Egypt
mona_ibrahim@mans.edu.eg



Dr. Amir Sasan Mozaffari Nejad 
Research Scholar
Department of Virology
Hamadan University of Medical Sciences, Hamadan
Iran
asmozaffarinejad@yahoo.in




Dr. Pawan K Dadheech 
Professor
Department of Microbiology
School of Life Sciences
Central University of Rajasthan, Rajasthan
India
pdadheech@curaj.ac.in



Dr. Hussein Hasan Abulreesh 
Associate Professor
Environmental and Public Health Microbiology,
Department of Biology
Umm Al-Qura University, Makkah
Saudi Arabia
hhabulreesh@uqu.edu.sa




Dr. Pranav Kumar Prabhakar 
Assistant Professor
Faculty of Applied Medical Sciences
Lovely Professional University
Phagwara, Punjab
India
pranav.16113@lpu.co.in



Dr. Hesam Kamyab 
Post Doctoral Fellow
UTM RAZAK School of Engineering and Advanced
Technology
University Teknologi Malaysia (UTM)
Malaysia
khesam2@live.utm.my



Dr. A.K. Srivastava 
Principal Scientist
Soil Science
ICAR- Central Citrus Research Institute, Nagpur
India
aksrivas2007@gmail.com



Dr. Kunal 
Associate Professor
Department of Microbiology
SGT University, Budhera
Gurugram, Haryana
India
kunal_pau@yahoo.co.in



Dr. Pushpanathan Muthurulan 
Research Associate
Department of Human Evolutionary Biology
Harvard University Cambridge, Massachusetts
USA
muthurulanp@fas.harvard.edu



Dr. Prashant Khare 
Scientist D & Ramalingaswami Fellow
Department of Microbiology
All India Institute of Medical Sciences, Bhopal
India
prashantkhare.microbiology@aiimsbhopal.edu.in




Dr. Parvez Akhtar 
Research Scientist
Aurora Research Institute
Milwaukee, WI 53233
USA
Parvez.Akhtar@aurora.org



Dr. Prosun Tribedi 
Assistant Professor
Department of Biotechnology,
The Neotia University,
South 24 Parganas, West Bengal
India
tribedi.prosun@gmail.com



Dr. Joaquim C.G. Esteves da Silva 
Professor
Faculty of Sciences
University of Porto, Porto
Portugal
jcsilva@fc.up.pt




Dr. Godfred A. Menezes 
Associate Professor and Clinical Microbiologist
Department of Medical Microbiology and
Immunology
RAK College of Medical Sciences
RAKMHSU, Ras Al Khaimah
UAE
godfred@rakhmsu.ac.ae



Dr. Ranga Rao Ambati 
Associate Professor
Department of Biotechnology,
Vignani's Foundation for Science,
Technology and Research, Andhra Pradesh
India
arangarao99@gmail.com




Dr. Abdur Rauf 
Assistant Professor
Department of Chemistry
University of Swabi, Pakhtunkhwa
Pakistan
abdurrauf@uoswabi.edu.pk



Dr. Mohammad Zubair 
Assistant Professor
Department of Medical Microbiology,
Faculty of Medicine,
University of Tabuk, Tabuk
Saudi Arabia
zmohammad@ut.edu.sa



Dr. Sedky Hassan Aly Hassan 
Associate Professor
Department of Botany & Microbiology
Faculty of Science,
New Valley University, El-Kharga, New Valley
Egypt
sedkyhassan@aun.edu.eg



Dr. Ramalingam Radhakrishnan 
Assistant Professor
P.G. and Research Department of Botany
Jamal Mohamed College,
Tiruchirappalli, Tamil Nadu
India
rkbot@jmc.edu



Dr. M. N. Khan
Editor
Journal of Pure and Applied Microbiology
editor@microbiologyjournal.org

Contents

LETTER TO THE EDITOR

- 693-694** Genetic Variant Severe Acute Respiratory Syndrome Coronavirus 2 Isolates in Thailand
Beuy Joob and Viroj Wiwanitkit

COMMENTARIES

- 695-698** COVID-19 Prophylaxis: The Desperate Need for Mankind
Johnson Christdas and Muthurulan Pushpanathan
- 699-701** Coronavirus Disease 2019 (COVID-19); Perspective of Pakistan
Tauseef Ahmad, Muhammad Waseem Shah, Hussain Ahmad and Muhammad Khan

MINI REVIEWS

- 703-708** Concerns on the Emerging Research of SARS-CoV-2 on Felines: Could They be Significant Hosts/Reservoirs?
D. Katterine Bonilla-Aldana, Julian Ruiz-Saenz, Marlen Martinez-Gutierrez, Ruchi Tiwari, Kuldeep Dhama, Javier A. Jaimes, and Alfonso J. Rodriguez-Morales
- 709-712** Importance of Bats in Wildlife: Not Just Carriers of Pandemic SARS-CoV-2 and Other Viruses
D. Katterine Bonilla-Aldana, S. Daniela Jimenez-Diaz, Shailesh Kumar Patel, Kuldeep Dhama, Ali A. Rabaan, Ranjit Sah, Manuel Sierra, Lysien I. Zambrano, Kovy Arteaga-Livias and Alfonso J. Rodriguez-Morales
- 713-716** Possibilities of "Crushing" the Transmission Curve of COVID-19 in Latin America - We Still Have Time
Samuel Pecho-Silva, Ana Claudia Navarro-Solsol, Kovy Arteaga-Livias, Vicky Panduro-Correa, Kuldeep Dhama and Alfonso J. Rodriguez-Morales
- 717-720** Economy or Health, Constant Dilemma in Times of Pandemic: The Case of Coronavirus Disease 2019 (COVID-19)
Jorge A. Sanchez-Duque, Juan Pablo Orozco-Hernandez, Daniel S. Marin-Medina, Kovy Arteaga-Livias, Samuel Pecho-Silva, Alfonso J. Rodriguez-Morales and Kuldeep Dhama
- 721-723** COVID-19 Infection in South Korea: Focusing on Age Distribution of Confirmed Cases
Hyunjoo Joo and Yun-Jung Kang

REVIEW ARTICLES

- 725-731** Coronaviruses and COVID-19 - Complications and Lessons Learned for the Future
Muhammad Bilal, Muhammad Imran Khan, Muhammad Shahzad Nazir, Ishtiaq Ahmed and Hafiz M.N. Iqbal
- 733-740** Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection
Ran Jing, Rama Rao Vunnam, Yuhong Yang, Adam Karevoll and Srinivas Rao Vunnam
- 741-747** SARS-CoV-2 (COVID-19): Zoonotic Origin and Susceptibility of Domestic and Wild Animals
Vinodh Kumar O.R., Ramkumar, B.S. Pruthvishree, Tripti Pande, D.K. Sinha, B.R. Singh, Kuldeep Dhama and Yashpal S. Malik

Contents

- 749-756** Food Safety and COVID-19: Precautionary Measures to Limit the Spread of Coronavirus at Food Service and Retail Sector
Muhammad Shahbaz, Muhammad Bilal, Abdul Moiz, Shagufta Zubair and Hafiz M.N. Iqbal
- 757-763** Molecular Characterization and Amino Acid Homology of Nucleocapsid (N) Protein in SARS-CoV-1, SARS-CoV-2, MERS-CoV, and Bat Coronavirus
Shantani Kannan, Kannan Subbaram, Sheeza Ali and Hemalatha Kannan
- 765-774** A Review of Potential Antiviral Drugs and Vaccines to Treat COVID-19
Sanjeet Singh and R. Jayaram
- 775-788** An Overview of Novel Coronavirus SARS-Cov-2 Spanning around the Past, Present and Future Perspectives
Shadma Yaqoob, Areena H. Siddiqui, R. Harsvardhan, J. Ahmad, V.K. Srivastava, M.K. Verma, P. Verma and A.N. Singh
- 789-798** Strengthening of Molecular Diagnosis of SARS-CoV-2 / COVID-19 with a Special Focus on India
Ragini Bhatia, Rajesh Chaudhary, Sandip Kumar Khurana, Ruchi Tiwari, Kuldeep Dhama, Vivek Kumar Gupta, Raj Kumar Singh and Senthilkumar Natesan
- 799-816** Different Cases of SARS-CoV-2 Infection and Its Impact on Health and Economy with Special Emphasis on Antiviral Drug Targets
Hiran Kanti Santra and Debdulal Banerjee
- 817-821** Immune Status of COVID-19 Patients with Reference to SARS and MERS
Barani Karikalan and Hari Kumar Darnal
- 823-829** COVID-19: Persistence, Precautions, Diagnosis and Challenges
Bhushan P. Bhusare, Vasudeo P. Zambare and Archana A. Naik
- 831-840** Proteome Organization of COVID-19: Illustrating Targets for Vaccine Development
Alok Bharadwaj, Nitin Wahi, Aditya Saxena and Divya Chaudhary
- 841-848** COVID-19 Evolution and Alternative Medicine - A Review
Shubhangi Goel and Anjana Goel
- 849-860** A Review on the Novel Coronavirus Disease based on In-silico Analysis of Various Drugs and Target Proteins
Gauravi N. Trivedi, Janhavi T. Karlekar, Hiren A. Dhameliya and Hetalkumar Panchal
- 861-867** Pentoxifylline: An Immunomodulatory Drug for the Treatment of COVID-19
Hiren A. Dhameliya, Vasudev R. Thakkar, Gauravi N. Trivedi, Sureshkumar N. Mesara and R.B. Subramanian
- 869-878** WisdomNet: Prognosis of COVID-19 with Slender Prospect of False Negative Cases and Vaticinating the Probability of Maturation to ARDS using Posteroanterior Chest X-Rays
Peeyush Kumar, Ayushe Gangal and Sunita Kumari

Contents

- 879-892** Global Status of COVID-19 Diagnosis: An Overview
Karthikeyan Ravichandran, Subbaiyan Anbazhagan, Shiv Varan Singh, Himani Agri, Ramkumar N. Rupner, Vinodh Kumar Obli Rajendran, Kuldeep Dhama and Bhoj R. Singh
- 893-902** How Close are We to a COVID-19 Vaccine?
Kayhan Ozkan
- 903-910** Analytical Review of COVID-19 Outbreak in India During the Global Pandemic
Parth Goel, Dweepna Garg and Amit Ganatra
- 911-920** Detection of Coronavirus Disease (COVID-19) using Radiological Examinations
Muhammad Shahzeb, Areena Khan and Anees Muhammad
- 921-929** COVID-19: Recent updates on SARS-CoV-2 and Preventing its Community Transmission in India by 21 Days Lockdown
Satyajeet K. Pawar and Shivaji T. Mohite
- 931-936** Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Emerging Zoonotic Respiratory Pathogen in Humans
Ashwini Malla, Balamurugan Shanmugaraj and Sathishkumar Ramalingam
- 937-943** Pharmacy Patronage: Identifying the Roles of Nepalese Pharmacists in Tackling COVID-19
Asmita Priyadarshini Khatriwada and Sunil Shrestha
- 945-956** SARS-CoV-2 / COVID-19 and its Transmission, Prevention, Treatment and Control - An Update
Pooja Sharma, Sonam Tripathi, Shailesh Kumar Patel, Kuldeep Dhama and Ram Chandra
- 957-961** Indian Economy Amid COVID-19 Lockdown: A Prespective
Amit Joshi, Preeti Bhaskar and Puneet Kumar Gupta
- 963-970** Study of Morphological Nature of Coronavirus: Causes and Prevention
Meetkamal and R.K. Dwivedi

RESEARCH ARTICLES

- 971-978** Genetic Variant of SARS-CoV-2 Isolates in Indonesia: Spike Glycoprotein Gene
Arif Nur Muhammad Ansori, Viol Dhea Kharisma, Sahal Sabilil Muttaqin, Yulanda Antonius and Arli Aditya Parikesit
- 979-988** Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19)
Abhi Bhadra, Shweta Singh, Shaswat Chandrakar, Vanshika Kumar, Sakshi Sankhla, Sayuj Raj T. and E. Selvarajan
- 989-998** *In silico* Molecular Docking Analysis Targeting SARS-CoV-2 Spike Protein and Selected Herbal Constituents
Anbazhagan Subbaiyan, Karthikeyan Ravichandran, Shiv Varan Singh, Muthu Sankar, Prasad Thomas, Kuldeep Dhama, Yashpal S. Malik, Raj Kumar Singh and Pallab Chaudhuri

Contents

- 999-1005** Construction of Epitope-Based Peptide Vaccine Against SARS-CoV-2: Immunoinformatics Study
Viol Dhea Kharisma and Arif Nur Muhammad Ansori
- 1007-1016** Epidemiological Determinants of Acute Respiratory Syndrome Coronavirus-2 Disease Pandemic and The Role of the Bacille-Calmette-Guerin Vaccine in Reducing Morbidity and Mortality
Bhoj R. Singh, Richa Gandharva, R. Karthikeyan, Shiv Varan Singh, Akanksha Yadav, Vinodh Kumar O.R., Dharmendra K. Sinha, Varsha Jayakumar, Kuldeep Dhama, Dharmender Kumar and Sumedha Gandharava
- 1017-1024** Correlation Between Temperature and COVID-19 (Suspected, Confirmed and Death) Cases based on Machine Learning Analysis
Mohammad Khubeb Siddiqui, Ruben Morales-Menendez, Pradeep Kumar Gupta, Hafiz M.N. Iqbal, Fida Hussain, Khudeja Khatoon and Sultan Ahmad
- 1025-1034** Elucidation on the Physicochemical Properties of Potential and Clinically Approved Antiviral Drugs: A Search for Effective Therapies against SARS-CoV-2 Infection
Derick Erl P. Sumalapao
- 1035-1042** Distribution of COVID-19 and Phylogenetic Tree Construction of SARS-CoV-2 in Indonesia
Dora Dayu Rahma Turista, Aesthetica Islamy, Viol Dhea Kharisma and Arif Nur Muhammad Ansori
- 1043-1052** 100 Days of COVID-19 in India: Current and Future Trends
Sheetal Gouda, G. Naveen and F. Sneha Kukanur
- 1053-1064** Comparative Analysis of SARS-CoV2 with Special Emphasis on Genome Sequences
Kumar Sharp and Shubhangi Dange
- 1065-1071** In silico Study of Pharmacological Treatments against SARS-CoV2 Main Protease
Youness Kadil, Mohamed Mouhcine and Houda Filali

SHORT COMMUNICATIONS

- 1073-1075** South Korea's COVID-19 Infection Status: From the Perspective of Reconfirmation after Complete Recovery
Yun-Jung Kang and Hyunjoo Joo
- 1077-1081** A Lung Transcriptomic Analysis for Exploring Host Response in COVID-19
Aditya Saxena, Uma Chaudhary, Alok Bharadwaj, Nitin Wahi, Jitender Reddy Kalli, Shravya Gupta, Sparsh Kumar, Somya Gupta and Utkarsh Raj